On February 7, 2020 Oragenics, Inc. (NYSE American: OGEN), a leader in the development of effective treatments for oral mucositis and new antibiotics against infectious diseases, reported that Alan Joslyn, Ph.D., president and CEO of Oragenics, Inc., will present a corporate overview at the 22nd Annual BIO CEO & Investor Conference being held on February 10 and 11, 2020, at the New York Marriott Marquis in New York City (Press release, Oragenics, FEB 7, 2020, View Source [SID1234554055]). Dr. Joslyn will present on Monday, February 10, 2020, at 10:45 am ET, in the Odets room, 4th Floor.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors or others interested in meeting with management are encouraged to request a meeting through the conference’s one-on-one meetings system or contact John Marco of CoreIR at johnm@coreir.com.

About the BIO CEO & Investor Conference

The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Each year, the BIO CEO & Investor Conference provides a forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to meet.